Traditionally, the approach is to initiate monotherapy first, followed by combination therapy that targets two main defects in T2DM. Repaglinide, a rapidly acting insulin secretagog, stimulates ...

the risk of T2DM was twice as low in patients with optimally controlled blood pressure than in those who had uncontrolled blood pressure, despite antihypertensive therapy. This study allows ...

This review explores the role of flavonoids in T2DM treatment, with a particular focus on their impact on the enteroendocrine system. Flavonoids are categorized into several subclasses based on ...